ArticleJournal of cancer research and clinical oncology2019
Intratumor heterogeneity and tissue distribution of KRAS mutation in non-small cell lung cancer: implications for detection of mutated KRAS oncogene in exhaled breath condensate.
Article in Journal of cancer research and clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 37 citations in OpenAlex.
- Trial
- Article
- The Role of Exhaled Breath Condensate in Chronic Inflammatory and Neoplastic Diseases of the Respiratory Tract.International journal of molecular sciences · 2024Review
- Review
- Oncogenic alterations in advanced NSCLC: a molecular super-highway.Biomarker research · 2024Review
- Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies.Exploration of targeted anti-tumor therapy · 2023Review
- Non-Invasive Biomarkers for Early Lung Cancer Detection.Cancers · 2022Review
- The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target-a narrative review.Translational lung cancer research · 2022Review
- The path to the clinic: a comprehensive review on direct KRASJournal of experimental & clinical cancer research : CR · 2022Review
- Targeting the "undruggable" RAS with biologics.Advances in cancer research · 2022Review
- Targeting the KRAS α4-α5 allosteric interface inhibits pancreatic cancer tumorigenesis.Small GTPases · 2022Article
- Targeting Oncogenic KRAS in Non-Small-Cell Lung Cancer.Cancers · 2021Review
- KRAS G12C Mutations in NSCLC: From Target to Resistance.Cancers · 2021Review
- Oncogenic driver mutations in non-small cell lung cancer: Past, present and future.World journal of clinical oncology · 2021Review
- Targeting KRAS: The Elephant in the Room of Epithelial Cancers.Frontiers in oncology · 2021Review
- An Update on the Use of Exhaled Breath Analysis for the Early Detection of Lung Cancer.Lung Cancer (Auckland, N.Z.) · 2021Review
- Inhibition of RAS: proven and potential vulnerabilities.Biochemical Society transactions · 2020Review
- Overcoming Resistance to Drugs TargetingInnovation (Cambridge (Mass.)) · 2020Article
- Early diagnosis and screening in lung cancer.American journal of cancer research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
purposeMutated KRAS oncogene in exhaled breath condensate (EBC) can be a genetic marker of non-small cell lung cancer (NSCLC). However, a possibility of inhomogeneous distribution in cancer tissue and intratumor heterogeneity of KRAS mutation may decrease its significance. We investigated a status of KRAS point mutation and its sequence at codon 12 in 51 NSCLC patients after tumor resection. The comparison of KRAS mutation status between EBC-DNA and cancer tissue was performed in 19 cases.
methodsFive cancer tissue samples from disparate tumor regions and one from normal lung were harvested at surgery. EBC was collected for DNA analysis the previous day. KRAS point mutations at codon 12 were detected using mutant-enriched PCR technique and pyrosequenced.
resultsForty-six cancers revealed concordance of KRAS mutation status: 27 contained mutated KRAS and 19 had only wild KRAS. Five NSCLCs revealed inhomogeneous distribution of KRAS mutation. Two different mutations were found in 14 NSCLCs and the most frequent one was G12D and G12V (n = 8). No mutated KRAS was found in normal lung. The concordance ratios of KRAS sequence in codon 12 between EBC-DNA and cancer were 18/19 for NSCLC patients and 11/12 for KRAS mutation positive NSCLC.
conclusionsIntratumor heterogeneity and inhomogeneous distribution of KRAS point mutation in codon 12 in cancer tissue can occur in NSCLCs. There was a high accordance between KRAS mutation status in EBC-DNA and cancer tissue in NSCLC patients what suggests usefulness of monitoring KRAS mutation in EBC-DNA as a biomarker of NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.